Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features.

Journal: EBioMedicine
Published Date: May 28, 2025

Abstract

BACKGROUND: Ductal Carcinoma In Situ (DCIS) can progress to ipsilateral invasive breast cancer (IBC) but over 75% of DCIS lesions do not progress if untreated. Currently, DCIS that might progress to IBC cannot reliably be identified. Therefore, most patients with DCIS undergo treatment resembling IBC. To facilitate identification of low-risk DCIS, we developed deep learning models using histology whole-slide images (WSIs) and clinico-pathological data.

Authors

  • Shannon Doyle
    Centrum Wiskunde & Informatica (CWI), 1090 GB Amsterdam, The Netherlands.
  • Esther H Lips
    The Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.
  • Eric Marcus
    AI for Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: e.marcus@nki.nl.
  • Lennart Mulder
    The Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.
  • Yat-Hee Liu
    The Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.
  • Francesco Dal Canton
    Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
  • Timo Kootstra
    Experimental Psychology, Helmholtz Institute, Utrecht University, The Netherlands.
  • Maartje M van Seijen
    Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
  • Ihssane Bouybayoune
    School of Cancer & Pharmaceutical Sciences, King's College London, UK.
  • Elinor J Sawyer
    School of Cancer & Pharmaceutical Sciences, King's College London, UK.
  • Alastair M Thompson
    Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
  • Sarah E Pinder
    School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
  • Clara I Sanchez
  • Jonas Teuwen
    Department of Radiology and Nuclear Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
  • Jelle Wesseling
    The Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.

Keywords

External Resources

Popular Topics
Recent Journals